RSV vaccine study for healthy women aged 18-49
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new vaccine (MKK900) to see if it is safe and works well in healthy adult women. It is designed to protect against RSV, a common virus that can be serious in newborns and older adults. The vaccine is being developed for use during pregnancy to pass protection to babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 49 years old.
- You are generally healthy with no serious medical conditions.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
- You agree to use effective birth control for 28 days before and 90 days after the shot.
- You have not had an RSV infection or RSV vaccine in the past.
- You are not taking steroids, have a weak immune system, or certain chronic illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.